Correspondence 0001193125-23-232439 from T2 Biosystems, Inc. (TTOO) (CIK 0001492674)
T2 Biosystems, Inc. (TTOO) (CIK 0001492674)
Date: Sept. 11, 2023 · CIK: 0001492674 · Accession: 0001193125-23-232439
AI Filing Summary & Sentiment
File numbers found in text: 333-274182
Letter
T2 Biosystems, Inc.
101 Hartwell Avenue
Lexington, MA 02421
September 11,
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: T2 Biosystems, Inc.
Registration Statement on Form S-3
File No. 333-274182
To the addressee set forth above:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of T2 Biosystems, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:30 P.M. Eastern Time on September 12, 2023, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact N. Danny Shulman, Esq. of Latham & Watkins LLP at (212) 906-4510, or in his absence, Evan G. Smith, Esq. of Latham & Watkins LLP at (617) 948-6089. Thank you for your assistance and cooperation in this matter.
Very truly yours,
T2 BIOSYSTEMS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP T2 Biosystems, Inc. 101 Hartwell Avenue Lexington, MA 02421 September 11, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: T2 Biosystems, Inc. Registration Statement on Form S-3 File No. 333-274182 To the addressee set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of T2 Biosystems, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:30 P.M. Eastern Time on September 12, 2023, or as soon as practicable thereafter. If you have any questions or require additional information, please contact N. Danny Shulman, Esq. of Latham & Watkins LLP at (212) 906-4510, or in his absence, Evan G. Smith, Esq. of Latham & Watkins LLP at (617) 948-6089. Thank you for your assistance and cooperation in this matter. Very truly yours, T2 BIOSYSTEMS, INC. By: /s/ Michael T. Gibbs Michael T. Gibbs General Counsel cc: Evan G. Smith, Latham & Watkins LLP N. Danny Shulman, Latham & Watkins LLP